InvestorsHub Logo
Followers 467
Posts 26912
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 142

Thursday, 11/15/2012 9:37:19 AM

Thursday, November 15, 2012 9:37:19 AM

Post# of 212
8:01AM Incyte achieves $50 mln milestone as Oral JAK1/JAK2 inhibitor Baricitinib advances into Phase III development for rheumatoid arthritis (INCY) 16.63 : Co announces it has earned a $50 mln milestone payment from Eli Lilly (LLY) based on the formal initiation of the rheumatoid arthritis Phase III program for baricitinib, Incyte's oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INCY News